N4 Pharma MTAs demonstrate commercial interest (Analyst Interview)

N4 Pharma plc (LON:N4P) is the topic of conversation when SP Angel Analyst Vadim Alexandre joins DirectorsTalk. Vadim talks us through the main points of their latest research note, explains what the current vaccine landscape means for the company, why someone might want to invest in the company and what can be expected from N4 over the coming months.

N4 Pharma, are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.

You might also enjoy reading  N4 Pharma's proof of concept work is extremely encouraging

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp
Vadim Alexandre
N4 Pharma MTAs demonstrate commercial interest (Analyst Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions